Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants.

Skaggs BJ, Gorre ME, Ryvkin A, Burgess MR, Xie Y, Han Y, Komisopoulou E, Brown LM, Loo JA, Landaw EM, Sawyers CL, Graeber TG.

Proc Natl Acad Sci U S A. 2006 Dec 19;103(51):19466-71.

2.
3.

Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib.

Griswold IJ, MacPartlin M, Bumm T, Goss VL, O'Hare T, Lee KA, Corbin AS, Stoffregen EP, Smith C, Johnson K, Moseson EM, Wood LJ, Polakiewicz RD, Druker BJ, Deininger MW.

Mol Cell Biol. 2006 Aug;26(16):6082-93.

4.

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.

Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen TT, Huang F, Decillis AP, Sawyers CL.

N Engl J Med. 2006 Jun 15;354(24):2531-41.

5.

The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants.

Tokarski JS, Newitt JA, Chang CY, Cheng JD, Wittekind M, Kiefer SE, Kish K, Lee FY, Borzillerri R, Lombardo LJ, Xie D, Zhang Y, Klei HE.

Cancer Res. 2006 Jun 1;66(11):5790-7.

6.

Detection of BCR-ABL mutations and resistance to imatinib mesylate.

Branford S, Hughes T.

Methods Mol Med. 2006;125:93-106.

PMID:
16502579
7.
8.

Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680.

Young MA, Shah NP, Chao LH, Seeliger M, Milanov ZV, Biggs WH 3rd, Treiber DK, Patel HK, Zarrinkar PP, Lockhart DJ, Sawyers CL, Kuriyan J.

Cancer Res. 2006 Jan 15;66(2):1007-14.

9.

Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib.

O'Hare T, Walters DK, Stoffregen EP, Sherbenou DW, Heinrich MC, Deininger MW, Druker BJ.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6987-93.

10.

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.

Carter TA, Wodicka LM, Shah NP, Velasco AM, Fabian MA, Treiber DK, Milanov ZV, Atteridge CE, Biggs WH 3rd, Edeen PT, Floyd M, Ford JM, Grotzfeld RM, Herrgard S, Insko DE, Mehta SA, Patel HK, Pao W, Sawyers CL, Varmus H, Zarrinkar PP, Lockhart DJ.

Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):11011-6.

11.

Dynamics of chronic myeloid leukaemia.

Michor F, Hughes TP, Iwasa Y, Branford S, Shah NP, Sawyers CL, Nowak MA.

Nature. 2005 Jun 30;435(7046):1267-70.

PMID:
15988530
12.

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.

Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H.

PLoS Med. 2005 Mar;2(3):e73.

13.

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B.

N Engl J Med. 2005 Feb 24;352(8):786-92.

14.

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

Weisberg E, Manley PW, Breitenstein W, Brüggen J, Cowan-Jacob SW, Ray A, Huntly B, Fabbro D, Fendrich G, Hall-Meyers E, Kung AL, Mestan J, Daley GQ, Callahan L, Catley L, Cavazza C, Azam M, Neuberg D, Wright RD, Gilliland DG, Griffin JD.

Cancer Cell. 2005 Feb;7(2):129-41. Erratum in: Cancer Cell. 2005 Apr;7(4):399. Mohammed, Azam [corrected to Azam, Mohammad].

15.

Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance.

Burgess MR, Skaggs BJ, Shah NP, Lee FY, Sawyers CL.

Proc Natl Acad Sci U S A. 2005 Mar 1;102(9):3395-400.

16.

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, Castaneda S, Cornelius LA, Das J, Doweyko AM, Fairchild C, Hunt JT, Inigo I, Johnston K, Kamath A, Kan D, Klei H, Marathe P, Pang S, Peterson R, Pitt S, Schieven GL, Schmidt RJ, Tokarski J, Wen ML, Wityak J, Borzilleri RM.

J Med Chem. 2004 Dec 30;47(27):6658-61.

PMID:
15615512
17.

Overriding imatinib resistance with a novel ABL kinase inhibitor.

Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL.

Science. 2004 Jul 16;305(5682):399-401.

18.

A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient.

Tamborini E, Bonadiman L, Greco A, Albertini V, Negri T, Gronchi A, Bertulli R, Colecchia M, Casali PG, Pierotti MA, Pilotti S.

Gastroenterology. 2004 Jul;127(1):294-9.

PMID:
15236194
19.
20.

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.

Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL.

Science. 2001 Aug 3;293(5531):876-80.

Supplemental Content

Support Center